Compare Corning Incorporated (GLW) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corning Incorporated vs ResMed Inc. — how do they compare? Corning Incorporated trades at $156.61 (market cap $131.65B), while ResMed Inc. trades at $230.12 (market cap $31.89B). The key difference: Corning Incorporated is far larger — about 4.1× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.16%). Which is the better fit depends on your goals — on Pluang, investors hold Corning Incorporated for 36 Days and ResMed Inc. for 51 Days on average.
| GLW | RMD | |
|---|---|---|
Market Cap | $131.65B | $31.89B |
Volume | 8,992,522 | 618,314 |
Sector | Technology | Health |
52-Week High | $255.79 | $277.88 |
52-Week Low | $78.03 | $182.82 |
Typical Hold Time | 36 Days | 51 Days |
Enterprise Value | $138.52B | $31.24B |
Dividend Yield | 0.73% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Corning (GLW) trades at $155.95, down 4.45% today amid a bearish technical outlook despite strong fundamentals. The company recently secured a significant $3B+ fiber supply agreement with AT&T, boosting its optical communications segment. GLW has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Analyst consensus remains positive with a $171.25 price target, though technical indicators show selling pressure with support at $149 and resistance at $158.
GLW presents a compelling long-term opportunity with strong revenue growth projections and strategic positioning in fiber optics for AI infrastructure. However, elevated valuation multiples (P/E 70.43) and ongoing patent litigation investigations pose near-term risks. The stock's current technical weakness may offer entry points for investors bullish on the company's fiber optic expansion and AI-driven connectivity demand.
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
